Liu FC, et al. – The clinicians wished to determine the impact of immunosuppressive therapy on new–onset diabetes after liver transplantation (NODALT). Their findings revealed that tacrolimus (TAC)–based immunosuppression leads to higher NODALT incidence than cyclosporine (CsA)–based regimen, and TAC–CsA conversion due to any causes might contribute to worse clinical outcomes. Hence, it was essential to implement risk stratification before prescribing immunosuppressants for liver transplant recipients.